

EDITORIAL





Since its founding in 1999, Ceva has maintained a remarkable trajectory of constant growth despite the health and geopolitical crises that have marked recent years. Ceva is **led by experienced veterinarians** with extensive knowledge of the field, and **its success is based on its capacity for innovation and commitment beyond animal health**. We have a clear mission: **to drive innovative health solutions for all animals, contributing to the future of our diverse planet**, through the work of our more than 6,700 passionate employees spread across 47 countries.

One key attribute that makes us stand out is our early commitment to our "One Health" approach, which we first inaugurated in 2010.

In concrete terms, we are making massive investments in preventive medicine. These efforts have allowed us to substantially increase the share of vaccines and other preventive health solutions in our product portfolio. Our goal to make these products account for 50% of our revenues - initially planned for 2025 - was achieved by 2021. We firmly believe that preventive medicine plays an essential role in saving animals from unnecessary suffering and improving their quality of life. We have also focused our efforts on equipment and services, so as to ensure the proper administration of our products.

The fight against zoonoses - diseases transmitted from animals to humans - is another key aspect of preventive medicine. To date we have developed more than 50 vaccines against no less than 19 zoonotic diseases. As veterinarians, it is our duty to protect animals, in order to make sure people stay healthy too. It has been estimated that 75% of new human infectious diseases are of animal origin.

We attach great importance to supporting our customers and partners on a daily basis in the field, while keeping our focus on the development of more sustainable agriculture. We work closely with livestock owners to help them meet the challenges of our time: feeding a growing global population whilst preserving the environment. The World Organization for Animal Health, estimates 20% of global livestock production is lost to disease each year, which according to an Oxford Analytica study done for HealthforAnimals translates into losses of approximately 80 billion kg, equal to the annual consumption needs of 1.6 billion people.

At the heart of our "One Health" actions is the great passion we put into defending the precious bond that unites humans and animals. For example, we actively support numerous assistance dog associations around the world.

We are also very conscious of our responsibility towards society and the environment. As part of our "One Planet" commitment, we have implemented more sustainable and responsible practices at our company. We are making considerable efforts to reduce our carbon footprint, manage water consumption efficiently, and minimize waste at all our facilities.

Finally, consistent with our pledge to care for all animals, we created the Ceva Wildlife Research Fund, a one-of-a-kind endowment tasked with providing funding for the preservation of wild animal health.

In short, Ceva remains resolutely committed to contributing to a better future for all animals, for people, and for our planet.

Manc Pnikazsky
Chairman and CEO, Ceva Santé Animale







OUR HISTORY

REVIEW OF KEY DATES IN THE COMPANY'S RISE TO SUCCESS

◎─ 1999

Ceva Santé Animale was formed when management conducted its first LMBO (leveraged management buyout).

2005

The acquisition of Biomune, producers of avian vaccines, permitted a vital return to the key US market. The portfolio included new technology vaccines - this was the birth of the Vectormune product line.

2007

Ceva management and its employees became majority shareholders during the third financial round.

2010

In its first decade, Ceva became the fastest-growing veterinary company.

Acquisition of Vectra, a key solution against parasites, in the United States.

2011

Ceva Huadu, dedicated to avian vaccines, became the company's first joint venture established in China.

2013

The acquisition of Sogeval allowed Ceva to become a leader in France and to enter the pet dermatology market with the Douxo product line.

● 2014

Capital restructuring to support the launch of the "Ambition 2020" business plan.

Temasek, CDC, Sofiproteol and Merieux Development joined as investors alongside "Friends of Ceva" to help accelerate the company's growth.

2017

Ceva entered the top 5 on the Brazilian market with the acquisition of Circovac and the integration of Hertape-Inova.

Creation of Ceva Ebvac, a new joint venture in China dedicated to pig vaccines.

2019

Creation of a global swine innovation center with the acquisition of IDT's veterinary business.

2020

Ceva achieved its "Ambition 2020" growth targets and successfully refinanced the company to help ensure its future growth. Téthys, PSP, Mitsui, Klocke and Continental Grain became shareholders.

2022

Ceva continued its expansion, first in Asia with the creation of a joint venture with Mitsui & Co., Ltd, and then in South America with the acquisition in Argentina of a biotech campus and a company, Zoovet. Ceva also expanded its oral rabies vaccines portfolio with the acquisition of Canadian company Artemis Technologies, Inc.

PRESS KIT

5

CEVA, AN ANIMAL HEALTH COMPANY

...A GLOBAL LEADER

Led by experienced veterinarians, Ceva's mission is to provide innovative health solutions for all animals, to ensure the highest level of care and well-being.

The company's portfolio of solutions includes preventive medicines, such as vaccines, veterinary pharmaceuticals and animal well-being products both for livestock and pets, as well as equipment & services so that it can offer its clients the best possible experience.

CEVA IN BRIEF



2022 revenues: €1,5 billion



R&D investments €120 million /year




5th biggest player in the global market



Group workforce 6,700 – 1,700 in France




Present in **47** countries **15** R&D centers



CEVA, AN ANIMAL HEALTH COMPANY

...A GLOBAL LEADER





CEVA IN FRANCE



The largest
French animal
health company



7 production facilities

Plouédern

Loudéac






more than 1,700 employees in France



4 R&D facilities



With a team of more than 1,700 employees spread across the country, Ceva has deep roots in the domestic market, a fact we are very proud of.

90% of the products and equipment we market in France are manufactured here in the country. Local production ensures the priority supply of trademarked veterinary medicines to our customers and partners in France.

Our strong geographical presence in France is a unique asset that helps us better understand the needs of French veterinarians, livestock owners and pet parents.

This local commitment has also led us to give serious consideration to what are generally known as "minor" species (ducks, guinea fowl, geese, sheep). Ceva has always taken an active role in the preservation of agrobiodiversity, and provides support for species with smaller populations as well, as shown in our ranges of specific vaccines and our personalized autovaccine solutions.

Ceva is also working on several ambitious projects in France:

1. Building a new corporate headquarters, intended to showcase the company in a more representative way as:

- A responsible company: the aim is to make a building that is environmentally responsible, ambitious, and resolutely focused on innovation, that:
 - > will project Ceva's values beyond our borders.
 - > will be in step with the transformations underway in the professional world.
- A company committed to increasing the visibility of its region:
 - > The entire project, from architectural design to construction work and the services to be offered, is handled by companies local to the region.

The project extends over 11,000 m2 and will include a modular amphitheater and various "showcase" spaces for visitors.





2. The development of our brand new logistics platform in Montpon-Ménestérol (Dordogne).

This facility will be Ceva's first logistics platform in Europe.

- This ultra-modern, energy self-sufficient (geothermal energy, photovoltaic panels - parking shades, ecologically managed green spaces - conservation grazing areas), BREEAM-certified building will be used for the storage of pharmaceutical products and vaccines.
- It is our ambition to develop a flexible and efficient distribution network meeting the highest standards of performance and compliance so that we can serve our customers more sustainably.
- This logistics platform will employ 40 people. We also cooperate closely with the French Government Job Center (Pôle Emploi) to offer professional redeployment solutions to persons who have recently lost their jobs. Ceva wishes to have as positive an impact as possible in the local regions where it does business.



The Ceva Laval campus: A center of global innovation for pets

- The campus boasts a team of 30 experts specialized in dermatological topicals, working to develop a full range of solutions to help manage skin problems in dogs and cats. Beyond this line of products, a complete range of therapeutic solutions for the comprehensive management of skin conditions has been developed as well, including atopic canine dermatitis, which affects between 10% and 15% of dogs worldwide.
- The Ceva Laval Campus also has expertise in oral dosage forms, which make the administration of tablets easier, thus facilitating treatment compliance. These include patented dosage forms customized for use in dogs and cats (quarter-scored or oblong tablets), with precise and adjustable dosages (clover-shaped, quarter-scored tablets) and good palatability (specific flavors and ingredients), encouraging spontaneous intake by the animal and therefore better treatment compliance.





KIT CEVO

PRESS KIT

4 SPECIES

WE FOCUS ON











Companion Animals

We innovate to help pet owners live more harmoniously with their four-legged companions. In order to preserve the special bond that unites humans and animals Ceva concentrates its effort in 3 broad domains: behaviour in which the company has truly expended the boundaries of what is possible and established itself as a leader, cardiology & nephrology and dermatology & antibiotic therapy.

Furthermore, we've develoed education programs and dedicated resources to raise awareness among owners regarding the proper management and prevention of conditions arising in these domains.

Poultry

For 20 years, Ceva has established itself as an innovative leader in poultry vaccination, starting from the hatchery. This success was born from its early understanding of the major role that poultry farming would inevitably come to play in feeding a growing world population.

Ceva works to develop safe, effective and innovative vaccines for all players in the poultry production chain, to help improve the efficiency and sustainability of the sector, including minor species.

The services offered help ensure the optimal application of vaccines, an in-depth understanding of avian health, as well as the training and performance of concerned parties throughout the value chain.

Multidisciplinary teams provide poultry producers, veterinarians and hatchery professionals with the comprehensive service and support they need to ensure that each solution will meet their customers' requirements.



4 SPECIES

WE FOCUS ON











Swine

Pork is one of the major sources of animal protein. Although its consumption is unevenly distributed across different regions of the world, it currently accounts for almost a third of total global demand and is expected to increase further.

Sustainable pork production requires not only preventive measures, swine disease control, and good reproductive management practices, but the provision of solutions as well, in order to ensure the production of healthy, quality pork.

That's why Ceva is committed to preventive medicine, not only in terms of the research and development of vaccines, but in terms of treatments and support services provided to producers and veterinarians as well.

Ruminants

Ceva's ambition is to develop sustainable production in the sector by providing tailor-made solutions to care for and protect animals from birth and throughout their lives.


Our thirst for innovation has led us to develop unique solutions such as the vaccine for Q fever, a zoonotic disease that can affect all ruminants and may spread to humans, most often via the respiratory route.

In our training and prevention programs - Cevolution and beprecise we advocate for the responsible use of antibiotics and antiparasitics, thus helping to preserve their effectiveness for future generations.




OUR VALUES

« Our values are an integral part of our 'One Ceva' culture. They show our commitment to providing our customers with excellence through innovation. »



OUR VALUES



Customer and animal passion

It's not about us, it's about our customers. We listen and learn from them delivering specific solutions to their individual challenges and needs.

Passionate means putting our feelings into "hands on" service that goes beyond the normal and building long-term partnerships.

We are fully dedicated to prevent and treat diseases of all animals.

Entrepreneurial Spirit

Together, we create an environment which encourages everyone to make decisions and assume responsibility for them.

In an increasingly complex and competitive world, we are able to get straight to the point without losing sight of our long-term ambitions.

We promote a culture of courage that allows us to continually move forwards, forge new paths, keep our promises and achieve our common goals, while always learning from our mistakes.

Innovation

Innovation is embedded in our performance.

We identify the unmet needs of today, to meet the challenges of tomorrow by developing practical solutions.

Being innovative goes beyond product innovation and means constantly challenging ourselves to find new ways of creating added value.

Solidarity

We are a team of committed professionals working "Together, beyond animal health", who are continuously encouraged to grow and making people grow through our interactions with the outside world.

We create collective performance by promoting trust and team spirit.

As the One Ceva community, we overcome adversity by coming together in difficult times.





ZOOM ON CEVA'S 4 CSR PILLARS



Promoting and developing the human-animal bond

As one of the leaders in the pet behavior field, it is Ceva's responsibility to support veterinarians and owners with the aim of promoting their well-being and strengthening the vital bond between humans and animals.

In recent years, our partnerships with assistance dogs development associations have become a priority for Ceva. The company has chosen partners that allow it to have a concrete impact on the lives of beneficiaries in many countries around the world.



Advocating for animal welfare

Ensuring the health and welfare of all animals is Ceva's core concern.

The company has adopted a charter on animal welfare, and has also developed a training module accessible to all addressing this issue.

Ceva, in association with the WVA (World Veterinary Association), has also created the Global Animal Welfare Awards (now the WVA Global Veterinary Awards) which aim to reward people and organizations who work to protect and preserve the well-being of animals as well as promoting an animal welfare focused approach in their everyday lives.

Plus, Ceva has signed an agreement with the International Veterinary Association (IVSA), to support its standing committee for animal welfare, which sponsors national welfare projects proposed by student associations.



Preserving biodiversity including domesticated and wildlife endangered species

Ceva takes action to help protect global biodiversity, and animal biodiversity in particular. The company leverages its expertise and knowhow for the benefit of all animals, whether wild (in particular through its endowment fund) or domestic.

Furthermore, Ceva, through its employee-led biodiversity working group, is also now piloting a project to help preserve ecosystems at its major sites.



Promoting the positive role of animal proteins in people's development

Nearly a billion people worldwide suffer from malnutrition. Lack of access to animal protein can have tragic consequences on the development of children's brains and skeletons.

That's why Ceva works every day to contribute to a future where everyone has access to healthy, nutritious food in sufficient quantities. Whether in its day-to-day business of providing solutions to enable farmers to responsibly produce sufficient protein, or through the commitments made by its employees around the world to help people in need, Ceva is committed to working for this great cause.





Ceva Wildlife Research Fund, a one-of-a-kind endowment whose objective is to fund applied research projects in the interest of preserving the health of wild animals.







« A comprehensive approach to biodiversity is nothing new for Ceva. But by creating this endowment fund, we wanted to create a separate structure to give this activity a home. »

The Ceva Wildlife Research Fund is a legal entity separate from Ceva Santé Animale, is chaired by **Dr. Marc Prikazsky**.

Its director is Dr. Pierre-Marie Borne.

A scientific committee made up of 7 persons meets at least once a year, and is responsible for providing opinions on the various projects (selection, assessment and monitoring).

The risks arising from interactions between humans and wild animals are increasing: 75% of new infectious diseases affecting humans today are of animal origin and originate mainly among wildlife. There is therefore an urgent need to act to better understand the diseases from which these animals suffer and treat them more effectively in order to prevent their spread to humans.

With this endowment fund, it is now possible – by securing substantial funding – to finance applied research projects, the results of which will be quickly observable, with deadlines of three to five years maximum.

The Ceva Wildlife Research Fund thus contributes to the preservation of the wild animal health, a field of animal health that is underinvested in because it does not constitute an economically viable activity.

The 3 main missions of the Ceva Wildlife Research Fund:


- Taking action to preserve biodiversity
- Fighting against zoonoses
- Facilitating interactions between wildlife, farm animals and people





1ST PROJECT

financed by the Ceva Wildlife Research Fund:





Protecting the Australian koala

Ravaged by chlamydia, Australia's iconic koalas are no longer able to ensure the survival of their species.

Protection of Australia's iconic koala is the first project to be financed by the fund.

According to the Australian Koala Foundation, Australia's koala population declined by 30% between 2018 and 2021. There are two principal reasons for this worrying observation, which in February 2022 led Australia to declare the East Coast koala a threatened species:

- the destruction of their natural habitat due to fires or increasing urbanization of their territory,
- chlamydia, which affects the vast majority of individuals concentrated in eastern Australia.


This lethal disease is endemic in these sharply declining populations and impacts their reproduction and sustainability. That's why the Ceva Wildlife Research Fund provides support to the University of the Sunshine Coast in Brisbane (Australia), financing the final stages of vaccine development and the associated testing activities. Work to finalize a formulation of this vaccine candidate for local production is now underway. Ceva Wildlife Research Fund has also provided support to this research project by establishing additional studies in view of an official registration of this vaccine.





2ND PROJECT

funanced by the Ceva Wildlife Research Fund:



A vaccination program against avian influenza

The Ceva Wildlife Research Fund provides support to the Belgian animal park Pairi Daiza by financing a vaccination program against avian influenza, which is widespread in Europe and around the world and therefore threatens the zoo's birds.

When the animal park was hit by a case of avian flu in 2022, its veterinarian began looking for new solutions, beyond the biosecurity measures already in place, taking as an absolute priority the protection and well-being of those of the park's birds the most at risk, such as spectacled pelicans and wild peacocks.

The park's team then approached the Belgian reference laboratory, Sciensano. After a technical evaluation of several relevant options for the protection of their birds, they opted for an innovative and risk-free vaccine for their animals.

After obtaining all the necessary authorizations from the Belgian authorities and the Pairi Daiza ethics committee to implement the vaccination operation, a first injection procedure was performed on 01/03/23, followed by a second on 19/04/23; all vaccinated individuals are doing well.

This program to protect the pelicans and peacocks at the Pairi Daiza wildlife park is a great example of concrete collaboration, with a positive impact. Each party brought real added value to the protection of these rare animals: for its part, the Ceva Wildlife Research Fund supported this project by financing the vaccination campaigns, and contributing skills and equipment. The Sciensano Institute, contributed by ensuring the necessary serological and virological monitoring, as required by the Belgian authorities.





Together, beyond animal health

10 avenue de la Ballastière 33500 Libourne - France

Tel. +33 (0)5 57 55 40 40

www.ceva.com